DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Sprycel (Dasatinib) - Published Studies

 
 



Sprycel Related Published Studies

Well-designed clinical trials related to Sprycel (Dasatinib)

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. [2011.06]

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. [2010.06.17]

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. [2010.03]

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. [2010.02]

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. [2010.01.20]

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). [2009.09.15]

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. [2009.06.18]

Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. [2009.06]

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. [2007.06.15]

Well-designed clinical trials possibly related to Sprycel (Dasatinib)

Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. [2010.11]

Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. [2009.04]

Effect of antacid on imatinib absorption. [2009.02]

Other research related to Sprycel (Dasatinib)

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. [2014]

[Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia]. [Article in Chinese] [2013]

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. [2012]

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. [2012]

Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. [2011.11.29]

Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. [2011.09]

Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. [2011.07.25]

[Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib]. [2011.07]

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients. [2011.06.01]

Dasatinib for the treatment of chronic myeloid leukemia. [2011.06]

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. [2011.06]

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. [2011.06]

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? [2011.05.23]

A phase 2 trial of dasatinib in advanced melanoma. [2011.05.15]

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. [2011.05.15]

[Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase]. [2011.05]

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. [2011.05]

The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms. [2011.05]

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia. [2011.04]

Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia. [2011]

Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. [2010.10]

Phase II Study of Dasatinib in Patients With Advanced Non-Small-Cell Lung Cancer. [2010.09.20]

Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases. [2010.09]

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. [2010.08.15]

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. [2010.08.05]

Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application. [2010.08]

Pleural effusions due to dasatinib. [2010.07]

Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. [2010.07]

ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. [2010.06]

Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells. [2010.06]

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. [2010.06]

Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. [2010.05]

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. [2010.05]

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. [2010.04]

[Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib] [2010.03]

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic. [2010]

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. [2010]

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. [2010]

Flow cytometric determination of Src phosphorylation in pediatric patients treated with dasatinib. [2009.12]

Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. [2009.09.01]

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. [2009.09]

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. [2009.08]

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. [2009.07.21]

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. [2009.07.20]

Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. [2009.07.15]

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. [2009.07.07]

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. [2009.07.01]

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. [2009.06.01]

Practical management of dasatinib for maximum patient benefit. [2009.06]

A once-daily dasatinib dosing strategy for chronic myeloid leukemia. [2009.06]

Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. [2009.06]

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. [2009.05.01]

Once-daily dasatinib for treatment of patients with chronic myeloid leukemia. [2009.05]

Dasatinib in chronic myeloid leukemia: a review. [2009.04]

Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia. [2009.04]

Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. [2009.04]

Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. [2009.04]

New approved dasatinib regimen available for clinical use. [2009.03]

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. [2008.12]

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. [2008.12]

Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia. [2008.11]

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor. [2008.11]

[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias] [2008.10.01]

[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias] [2008.09]

Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. [2008.08.15]

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. [2008.08.15]

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. [2008.08.01]

Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. [2008.08]

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. [2008.07.01]

Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys. [2008.07]

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. [2008.07]

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. [2008.06.15]

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. [2008.06.15]

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. [2008.06]

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. [2008.06]

Initial testing of dasatinib by the pediatric preclinical testing program. [2008.06]

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. [2008.04]

Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib. [2008.03.01]

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. [2008.02.15]

[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia] [2008.01.28]

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. [2008.01.15]

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. [2008]

Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. [2008]

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. [2007.12.01]

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. [2007.12]

Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib. [2007.12]

Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. [2007.11]

Management of Bcr-Abl-positive leukemias with dasatinib. [2007.11]

Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. [2007.10.15]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017